Vis enkel innførsel

dc.contributor.authorDrosos, Petros
dc.contributor.authorBrønnick, Kolbjørn Kallesten
dc.contributor.authorJoa, Inge
dc.contributor.authorJohannessen, Jan Olav
dc.contributor.authorJohnsen, Erik
dc.contributor.authorKroken, Rune Andreas
dc.contributor.authorStain, Helen J.
dc.contributor.authorHegelstad, Wenche
dc.contributor.authorLarsen, Tor Ketil
dc.PublishedJournal of Clinical Psychopharmacology. 2020, 40 (6), 534-540.
dc.description.abstractBackground Remission in schizophrenia is difficult to achieve. Antipsychotic drugs are critical in the treatment of schizophrenia. International guidelines for the pharmacological treatment of schizophrenia recommend a 3-step algorithm with clozapine being the third-line antipsychotic agent. This study investigated the 1-year outcome and the application of the guidelines for the pharmacological treatment of nonremitted first-episode schizophrenia (FES) patients during the first year of follow-up. Methods A sample of 78 FES patients from the Norwegian TIPS (Early Treatment and Intervention in Psychosis) 2 study was assessed at the end of the first year of follow-up. The symptom remission criteria were those defined by the Remission in Schizophrenia Working Group. The adherence to the pharmacological guidelines was assessed by reading the medical files and by a digital search of the words “clozapine,” “klozapin,” and “Leponex” in the hospital electronic data system. Results The majority (n = 53, 67.9%) of the patients included were nonremitted at the 1-year follow-up. The majority of the nonremitted patients received either none (7.5%), one (56.6%), or 2 types (15.1%) of antipsychotic drugs during the first year of follow-up. Only 2 (3.8%) received treatment with clozapine, and 3 (5.7%) in total were offered it. Conclusions For our FES sample, there was a low 1-year remission rate and a poor adherence to the pharmacological guidelines. Higher adherence to treatment guidelines with a more intensified antipsychotic treatment, which in some cases will include clozapine, will enhance the quality of treatment and may enhance the rates of remission for schizophrenia.en_US
dc.publisherWolters Kluwer Healthen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleOne-year outcome and adherence to pharmacological guidelines in first-episode schizophrenia: Results from a consecutive cohort studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.source.journalJournal of Clinical Psychopharmacologyen_US
dc.identifier.citationJournal of Clinical Psychopharmacology. 2020, 40 (6), 534-540en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal